Continuous Monitoring Boosts Liver Assessment

• August 28, 2026

Correction: Hepatic origin of increased serum TFF3 in gastric cancer bearing subjects

• by Komei Kuge, Junko Mukohyama, Yoshimi Yasukawa, Yuko Ishibashi, Hiroki Masuda, Tomohiko Yasuda, Yasukazu Ohmoto, Hideyuki Takeshima, Akihisa Matsuda, Hiroshi Yoshida, Yasuyuki Seto, James R. Goldenring, Toshikazu Ushijima, Sachiyo Nomura

• August 25, 2026

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

• by

• August 26, 2026

• 5 min

Documented risk-based antithrombotic management and 30-day outcomes after endoscopic hemostasis for non-variceal upper gastrointestinal bleeding: a retrospective cohort study

• by Xiaoyun Zhao, Li Wang, Jianyi Li

• August 25, 2026